This research paper takes a look at the risk of breast cancer from doxorubicin exposure in female survivors of Hodgkin lymphoma who are between the ages of 15-50 years of age and five years post treatment. The period of treatment was between 1975 and 2008. The study was first presented in 2021 at the ASCO Annual Meeting.

Of note is that the authors found an increased risk of breast cancer in this cohort independent of whether or not radiation was also a part of the treatment protocol.

When thinking about cancer research, many people think of studies focused on evaluating new or better ways to treat the cancer itself. What may not come to mind is a type of research known as “survivorship research.”

Men with breast cancer tend to have a worse prognosis than women, as they commonly have more advanced disease at diagnosis. While many practitioners utilize mammography screening for women, there is less awareness of recommendations regarding screening for men.

Patients with cancer had a higher rate of acute MI when presenting to the ED with chest pain.

A Phase III trial has demonstrated that patients with advanced Stage III/IV classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated with brentuximab vedotin, a monoclonal antibody, and AVD (BV-AVD) a year after starting treatment.

The number of cancer survivors with self-reported functional limitations throughout the United States has more than doubled over the past 2 decades, according to data published in JAMA Oncology.

Childhood cancer survivors have increased rates of undergoing late, major surgical procedures 5 or more years after diagnosis, according to data from the Childhood Cancer Survivor Study.

The first study to demonstrate an association between therapeutic radiation dose to the large bowel and colorectal cancer.

In a new study, the majority of individuals treated as children for Hodgkin lymphoma who are now in their 30s, showed signs of being an average of 7.7 years older biologically than their peers and placing them at risk for cognitive problems.

This article describes the results of a study from the University of California San Francisco. It highlights one of the topics Dr. Micheal Stubblefield mentioned in his presentation at our conference. It comes from a paper that was published in the British Medical Journal Supportive and Palliative Care, July 2022. First author Steven W. Cheung, MD notes the marked incidence of hearing loss and tinnitus in survivors, owing to chemotherapy drugs that contained platinum as well as those that contained taxanes.